QTRX official logo QTRX
QTRX 1-star rating from Upturn Advisory
Quanterix Corp (QTRX) company logo

Quanterix Corp (QTRX)

Quanterix Corp (QTRX) 1-star rating from Upturn Advisory
$7.56
Last Close (24-hour delay)
Profit since last BUY7.69%
upturn advisory logo
Consider higher Upturn Star rating
BUY since 14 days
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock price based on last close icon Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • 1Y
  • 1M
  • 1W

Upturn Advisory Summary

12/12/2025: QTRX (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

Upturn 1 star rating for performance

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

1 star rating from financial analysts

4 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $6

1 Year Target Price $6

Analysts Price Target For last 52 week
$6 Target price
52w Low $4.05
Current$7.56
52w High $12.41

Analysis of Past Performance

Type Stock
Historic Profit -58.06%
Avg. Invested days 23
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 12/12/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 353.13M USD
Price to earnings Ratio -
1Y Target Price 6
Price to earnings Ratio -
1Y Target Price 6
Volume (30-day avg) 4
Beta 1.01
52 Weeks Range 4.05 - 12.41
Updated Date 12/14/2025
52 Weeks Range 4.05 - 12.41
Updated Date 12/14/2025
Dividends yield (FY) -
Basic EPS (TTM) -2.34

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -73.47%
Operating Margin (TTM) -62.01%

Management Effectiveness

Return on Assets (TTM) -11.28%
Return on Equity (TTM) -29.28%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 258444625
Price to Sales(TTM) 2.71
Enterprise Value 258444625
Price to Sales(TTM) 2.71
Enterprise Value to Revenue 2
Enterprise Value to EBITDA -1.49
Shares Outstanding 46710797
Shares Floating 36928622
Shares Outstanding 46710797
Shares Floating 36928622
Percent Insiders 6.55
Percent Institutions 81.81

About Quanterix Corp

Exchange NASDAQ
Headquaters Billerica, MA, United States
IPO Launch date 2017-12-07
President, CEO & Director Dr. Masoud Toloue Ph.D.
Sector Healthcare
Industry Medical Devices
Full time employees 471
Full time employees 471

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, the company offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology and immunology, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.